Neovasculgen(Neovasculgen) - 药物靶点：VEGF-A_在研适应症：外周动脉疾病_专利_临床

概要

基本信息

药物类型

基因疗法

别名

cambiogenplasmid、Vascular endothelial growth factor gene therapy、VEGF gene therapy

+ [1]

靶点

VEGF-A

作用方式

刺激剂、诱导剂

作用机制

VEGF-A刺激剂(血管内皮生长因子A刺激剂)、血管生成诱导剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

俄罗斯 (2011-12-07),

外周动脉疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

9

项与 Neovasculgen 相关的临床试验

NCT07391319

/ Recruiting临床3期

"Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Study of the Efficacy and Safety of the Drug Neovasculgen® Lyophilisate for the Preparation of a Solution for Intramuscular Administration 1.2 mg", Manufacturer Federal State Budgetary Institution "NMITs of Hematology" of the Ministry of Health of the Russian Federation, Russia in Patients With Diabetic Foot Syndrome"

The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.

开始日期2025-02-11

申办/合作机构-

NCT06473740

/ Recruiting临床4期IIT

Multicenter Randomized Prospective Controlled Trial of the Clinical Effectiveness of a Best Endovascular Treatment Versus a Best Endovascular Treatment in Combination With Gene Therapy for Severe Limb Ischemia

GENEVA is the world's first multicenter, randomized, prospective, controlled trial of the clinical effectiveness of best endovascular treatment versus best endovascular treatment combined with gene therapy for severe lower limb ischemia (Rutherford categories 4 and 5). The researchers hypothesized that the combination treatment would significantly reduce the number of re-interventions on the operated segment and high amputations, and also significantly increase the time interval between re-interventions.

开始日期2024-06-20

申办/合作机构-

NCT07391306

/ Recruiting临床2/3期

Double-blind, Placebo-controlled, Adaptive, Multicenter, Prospective, Randomized, Comparative, Parallel-group Study of the Efficacy and Safety of Neovasculgen (Plasmid Supercoiled Deoxyribonucleic Acid pCMV-VEGF165) in Painful Bladder Syndrome/Interstitial Cystitis (BPS/IC)

To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis and the prevention of secondary bladder shrinkage with a decrease in its volume.

开始日期2024-02-16

申办/合作机构-

100 项与 Neovasculgen 相关的临床结果

登录后查看更多信息

100 项与 Neovasculgen 相关的转化医学

登录后查看更多信息

100 项与 Neovasculgen 相关的专利（医药）

登录后查看更多信息

9

项与 Neovasculgen 相关的文献（医药）

2025-01-01·Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Neovasculgen® – has its effectiveness been proven? (Audiatur et altera pars)

Letter

作者: Vachev, A N ; Karpenko, A A ; Bazylev, V V ; Troitskiy, A V

2020-01-01·Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

Ways of limbs salvage in postoperative period of treatment of complications of diabetic foot syndrome

Article

作者: Krivoshchekov, E P ; Rodnianskiĭ, D V ; Aliapyshev, G S ; Romanov, V E ; El'shin, E B

2018-09-01·Therapeutic advances in cardiovascular disease

Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication

Article

作者: Bozo, Ilia ; Mzhavanadze, Nina ; Suchkov, Igor ; Staroverov, Ilia ; Kalinin, Roman ; Plaksa, Igor ; Deev, Roman ; Isaev, Artur ; Chervyakov, Yuriy

100 项与 Neovasculgen 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Neovasculgen	V09G	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
外周动脉疾病	俄罗斯	Artgen Biotech PJSC	2011-12-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病足溃疡	临床阶段不明	俄罗斯	Artgen Biotech PJSC	2015-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03068585 (Pubmed \| Ther Adv Cardiovasc Dis)	临床2/3期	间歇性跛行 \| 外周动脉疾病	100	pl-VEGF165	遞鑰壓襯窪醖夢糧選鏇(鹹積憲範構選觸網窪網) = 憲醖廠鏇鬱鑰網夢築獵鏇願壓鑰艱鏇窪餘淵壓 (獵遞衊膚餘獵醖襯選積 )	积极	2018-09-01
NCT02369809 (Pubmed \| Am J Cardiovasc Drugs)	临床4期	外周动脉疾病	210	Control group	範顧膚鹽顧壓製鑰淵製(淵鹹醖餘壓鹽遞顧餘築) = 糧壓獵鹽淵壓選選餘蓋繭網選遞餘廠選齋鹽齋 (構餘醖顧衊膚衊齋蓋鏇 )	积极	2017-06-01
NCT02369809 (Pubmed \| Am J Cardiovasc Drugs)	临床4期	外周动脉疾病	210	Treatment group	範顧膚鹽顧壓製鑰淵製(淵鹹醖餘壓鹽遞顧餘築) = 壓憲簾膚鹹顧餘鑰鬱觸繭網選遞餘廠選齋鹽齋 (構餘醖顧衊膚衊齋蓋鏇 )	积极	2017-06-01